mounjaro Drug Patent Profile

Which patents cover Mounjaro, and when can generic versions of Mounjaro launch?

Mounjaro is a drug marketed by Eli Lilly And Co and is included in one NDA. There are eight patents protecting this drug.

The generic ingredient in MOUNJARO is tirzepatide. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the tirzepatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Mounjaro

Mounjaro was eligible for patent challenges on May 13, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 19, 2028. This may change due to patent challenges or generic licensing.

There have been fourteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for mounjaro

US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	7
Drug Prices:	Drug price information for mounjaro
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for mounjaro
What excipients (inactive ingredients) are in mounjaro?	mounjaro excipients list
DailyMed Link:	mounjaro at DailyMed

See drug prices for mounjaro

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for mounjaro

Constraining patent/regulatory exclusivity:

NEW PATIENT POPULATION

NDA:

215866

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for mounjaro

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
First Affiliated Hospital of Wenzhou Medical University	PHASE2
Johns Hopkins University	PHASE2
University Medical Centre Ljubljana	PHASE4

See all mounjaro clinical trials

Pharmacology for mounjaro

Drug Class	GLP-1 Receptor Agonist Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Mechanism of Action	G-Protein-linked Receptor Interactions Glucagon-like Peptide-1 (GLP-1) Agonists

US Patents and Regulatory Information for mounjaro

mounjaro is protected by twenty-eight US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on NEW PATIENT POPULATION.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	MOUNJARO (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-002	May 13, 2022		RX	Yes	Yes	12,453,755
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-017	Jan 7, 2026		RX	Yes	Yes	12,343,382
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-017	Jan 7, 2026		RX	Yes	Yes

EU/EMA Drug Approvals for mounjaro

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Mounjaro	tirzepatide	EMEA/H/C/005620Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2022-09-15

International Patents for mounjaro

When does loss-of-exclusivity occur for mounjaro?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Finland

France

Hungary

Israel

Japan

Jordan

Lithuania

Luxembourg

Malaysia

Mexico

Moldova, Republic of

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering mounjaro around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	115542
Australia	2019289110
Australia	2022279524

Supplementary Protection Certificates for mounjaro

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3242887	CA 2023 00005	Denmark		PRODUCT NAME: TIRZEPATID OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/22/1685 20220919
3242887	301217	Netherlands		PRODUCT NAME: TIRZEPATIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/22/1685 20220919
3242887	PA2023504	Lithuania		PRODUCT NAME: TIRZEPATIDAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/22/1685 20220915

Mounjaro Market Dynamics and Financial Trajectory: Tirzepatide Revenue, Competition, Patents, and Generic Risk

Last updated: September 27, 2026

Eli Lilly’s Mounjaro, the tirzepatide brand approved for Type 2 diabetes, has become one of the pharmaceutical industry’s fastest-growing products. U.S. Mounjaro revenue increased from $279 million in 2022 to $5.16 billion in 2023 and $11.54 billion in 2024. Lilly’s separate obesity brand, Zepbound, generated $4.93 billion in 2024. Combined tirzepatide sales therefore reached approximately $16.47 billion in 2024, before accounting for international expansion and future indication growth. [1]

The commercial outlook remains strong, but the product faces supply constraints, reimbursement pressure, compounding competition, Novo Nordisk’s semaglutide franchise, and eventual patent challenges. The central protection is Lilly’s tirzepatide composition-of-matter patent estate, which is expected to limit conventional generic entry until the mid-2030s.

How much revenue does Mounjaro generate?

Mounjaro revenue has followed a steep launch curve driven by strong clinical demand, rapid physician adoption, and expansion of the incretin market.

Fiscal year	Mounjaro revenue	Year-over-year change
2022	$279 million	Launch year
2023	$5.16 billion	Approximately 18-fold increase
2024	$11.54 billion	124%
2025 outlook	Not included in this analysis	Subject to updated company guidance

Source: Eli Lilly annual reports. [1,2]

Mounjaro revenue excludes Zepbound, which uses the same active ingredient, tirzepatide, but is marketed for chronic weight management. Zepbound generated $4.93 billion in 2024, making tirzepatide a platform franchise rather than a single-brand product. [1]

What is Lilly’s total revenue exposure to tirzepatide?

Eli Lilly reported 2024 revenue of approximately $45.04 billion. Mounjaro and Zepbound together represented about 36.6% of that amount.

Product or franchise	2024 revenue	Share of Lilly revenue
Mounjaro	$11.54 billion	25.6%
Zepbound	$4.93 billion	10.9%
Combined tirzepatide products	$16.47 billion	36.6%
Lilly total revenue	$45.04 billion	100%

This concentration creates operating leverage for Lilly but also increases exposure to manufacturing interruptions, regulatory action, reimbursement changes, and patent litigation.

Why is Mounjaro demand growing so quickly?

Mounjaro combines glucose control with substantial weight loss. Tirzepatide is a dual GIP and GLP-1 receptor agonist. In the SURPASS clinical program, Lilly reported strong reductions in glycated hemoglobin and body weight in adults with Type 2 diabetes. [3]

The principal market drivers are:

1. High prevalence of Type 2 diabetes and obesity.
2. Weight loss outcomes that exceed those of several older diabetes therapies.
3. Increased physician familiarity with injectable incretin medicines.
4. Growing employer and insurer interest in obesity treatment.
5. Expanded prescribing through telehealth and specialty weight-management practices.
6. Potential future indications, including cardiovascular, obstructive sleep apnea, and metabolic disease applications.

The market is also benefiting from a broader change in treatment behavior. GLP-1 and GIP/GLP-1 therapies have moved from niche diabetes products toward chronic metabolic medicines with large eligible populations.

How does Mounjaro compare with Ozempic, Wegovy, and Trulicity?

Mounjaro competes primarily with Novo Nordisk’s semaglutide products and Lilly’s own older GLP-1 product, Trulicity.

Product	Active ingredient	Company	Primary positioning	Core commercial issue
Mounjaro	Tirzepatide	Eli Lilly	Type 2 diabetes	Supply, reimbursement, patent protection
Zepbound	Tirzepatide	Eli Lilly	Chronic weight management	Insurance coverage and manufacturing capacity
Ozempic	Semaglutide	Novo Nordisk	Type 2 diabetes	Mature blockbuster and strong physician awareness
Wegovy	Semaglutide	Novo Nordisk	Chronic weight management	Demand, supply, coverage
Trulicity	Dulaglutide	Eli Lilly	Type 2 diabetes	Older mechanism and declining growth

Tirzepatide has generally shown greater average weight reduction than semaglutide in comparative clinical data, although cross-trial comparisons must be interpreted carefully. In the SURMOUNT-5 trial, Lilly reported greater weight loss with tirzepatide than with semaglutide in adults with obesity or overweight without diabetes. [4]

Mounjaro’s commercial advantage is therefore based on both clinical differentiation and the ability to use different brands for diabetes and obesity. Its principal competitive risk is that Novo Nordisk can extend semaglutide into additional formulations, indications, and oral delivery systems.

What is the FDA regulatory status of Mounjaro?

The FDA approved Mounjaro on May 13, 2022, as an adjunct to diet and exercise for improving blood sugar in adults with Type 2 diabetes. [5]

The FDA approved Zepbound on November 8, 2023, for chronic weight management in adults with obesity or overweight with at least one weight-related condition. [6]

The regulatory distinction matters because the two products contain the same active ingredient but have different labels, promotional restrictions, reimbursement pathways, and patient populations.

What FDA exclusivity applies to Mounjaro?

Mounjaro received new chemical entity exclusivity associated with tirzepatide’s first approval. The five-year NCE period is expected to run until May 2027, subject to FDA Orange Book records and any regulatory adjustments. An ANDA applicant generally cannot file a standard generic application during the first four years of NCE protection, but a Paragraph IV filing may be possible after the fourth anniversary.

NCE exclusivity is separate from patent protection. It delays certain FDA approvals but does not replace the longer-term patent estate.

What patents protect Mounjaro and tirzepatide?

The core protection is Lilly’s composition-of-matter patent estate covering tirzepatide and related peptide compounds. One publicly identified U.S. patent associated with Lilly’s tirzepatide technology is U.S. Patent No. 10,034,938, which has an expiration date in 2036 based on publicly available patent records. [7]

Protection category	Commercial purpose	Expected risk window
Tirzepatide composition patents	Protect the active molecule	Generally extends into the mid-2030s
Peptide sequence and analog patents	Protect related compounds and structural variants	Patent-family dependent
Formulation and injectable-delivery patents	Protect concentration, stability, and delivery characteristics	Patent-family dependent
Manufacturing patents	Protect synthesis, purification, and scale-up processes	Patent-family dependent
Method-of-use patents	Protect diabetes, obesity, and other indications	Indication and patent dependent
FDA NCE exclusivity	Delays certain generic filings and approvals	Expected through 2027

The Orange Book remains the controlling source for listed patents and use codes relevant to an ANDA challenge. Patent expiration dates can differ by patent, patent-term adjustment, terminal disclaimer, pediatric extension, or regulatory listing status. [8]

What formulations are protected by Mounjaro patents?

The principal commercial formulation is a once-weekly sterile injectable solution delivered through a single-dose prefilled pen or related injection presentation. Relevant protection may include:

• Tirzepatide composition and sequence.
• Pharmaceutical compositions containing tirzepatide.
• Concentration and stability characteristics.
• Injectable delivery systems.
• Manufacturing, purification, and impurity-control processes.
• Indications involving glycemic control, weight management, and metabolic disease.

Formulation patents generally provide less protection than a valid composition patent because an ANDA applicant may attempt to design around specific formulation claims. A valid composition-of-matter patent is the primary barrier to a conventional tirzepatide generic.

When does Mounjaro lose exclusivity?

Mounjaro’s practical exclusivity timeline has several stages.

Date or period	Event
May 13, 2022	FDA approval of Mounjaro
May 13, 2026	Approximate four-year point relevant to certain Paragraph IV ANDA filings
May 13, 2027	Approximate end of five-year NCE exclusivity
2036	Expected expiration period for important core tirzepatide patent protection
After 2036	Potential generic entry, subject to patent litigation, regulatory approval, and surviving claims

The earliest theoretical generic filing date and the earliest commercial launch date are different. A Paragraph IV applicant can file before patent expiry by asserting that the listed patents are invalid, unenforceable, or not infringed. If Lilly sues within the statutory period, FDA approval can be delayed by a 30-month stay, subject to court decisions and statutory exceptions.

A first successful Paragraph IV applicant may qualify for 180 days of generic exclusivity under the Hatch-Waxman framework. That outcome would depend on the timing and substance of the challenge.

Which companies are challenging Mounjaro?

Through the period covered by this analysis, public competitive pressure has been more visible from manufacturers of alternative incretin products and compounders than from a mature wave of ANDA applicants.

The principal competitive groups are:

• Novo Nordisk, with Ozempic and Wegovy.
• Manufacturers of GLP-1 products targeting diabetes and obesity.
• Compounding pharmacies and outsourcing facilities producing compounded tirzepatide during periods of FDA-recognized shortage.
• Future generic-drug companies evaluating Paragraph IV strategies.

Lilly has pursued litigation and enforcement actions against entities marketing compounded or unauthorized tirzepatide products, including claims involving trademarks, misleading promotion, and unauthorized use of Lilly’s product identity. These disputes are not equivalent to a traditional Paragraph IV patent challenge because the defendants are generally not seeking FDA approval through the ANDA pathway.

What is the biosimilar risk for Mounjaro?

Mounjaro is not a biologic and therefore does not face biosimilar competition under the Biologics Price Competition and Innovation Act. Tirzepatide is a synthetic peptide drug regulated through the small-molecule drug framework.

Potential competitors would more likely pursue:

• An ANDA for a therapeutically equivalent tirzepatide product.
• A patent challenge under Paragraph IV.
• A 505(b)(2) application if the product differs materially in formulation, delivery, or presentation.
• A non-identical peptide or alternative incretin product.

The regulatory pathway may be more complex than for a conventional small-molecule tablet because peptide characterization, impurity profiles, device compatibility, and manufacturing consistency can affect FDA review. Those factors increase development cost but do not eliminate eventual generic risk.

How are supply constraints affecting Mounjaro’s market dynamics?

Supply has been one of the principal limits on Mounjaro and Zepbound sales. Lilly has invested heavily in manufacturing capacity for injectable medicines, including a reported $5.3 billion expansion of its Lebanon, Indiana, site and broader capital spending across its global network. [9]

Supply constraints affect the franchise in four ways:

1. They limit prescriptions even when demand exceeds production.
2. They encourage patients to switch between branded products, pharmacies, and compounded versions.
3. They increase regulatory scrutiny of compounding and shortage declarations.
4. They accelerate Lilly’s need to finance manufacturing before full demand is predictable.

The supply problem is commercially favorable when it reflects excess demand, but it can reduce realized revenue if patients cannot consistently obtain refills. It also creates reputational and adherence risks for a chronic therapy.

What licensing deals affect Mounjaro?

No major third-party license comparable to a co-development or co-commercialization agreement has been publicly identified as the central commercial basis for tirzepatide. Lilly developed and commercializes Mounjaro and Zepbound.

The relevant strategic transactions are primarily internal manufacturing investments, research programs, and business-development activity around adjacent metabolic medicines. Lilly’s competitive position depends more on proprietary molecule ownership, clinical development, manufacturing scale, and market access than on a license from an external originator.

What generic launch scenarios exist for Mounjaro?

The most likely generic-entry scenarios are:

Scenario one: Core patent survives

If Lilly’s primary composition patents survive litigation, conventional generic entry could be deferred until the mid-2030s. Formulation or method-of-use patents would have less significance if the core molecule remains protected.

Scenario two: Early Paragraph IV settlement

Lilly could settle with one or more generic applicants. A settlement might permit an agreed launch date before the latest patent expiration, subject to antitrust review and settlement terms. The commercial result would depend on whether the settlement grants an authorized generic, limits launch volume, or preserves certain indications.

Scenario three: Core patent invalidation

If a court invalidates or narrows a key composition patent, an approved ANDA could create a rapid price and share shock. Mounjaro’s high sales base would make the product an attractive target for multiple generic manufacturers.

Scenario four: Compounded-product substitution

Compounded tirzepatide can pressure branded demand before patent expiry, but this pathway is constrained by federal compounding rules, shortage status, state pharmacy regulation, quality concerns, and Lilly enforcement actions.

How strong is the Mounjaro patent estate?

The estate is commercially strong because it combines a high-value active ingredient with multiple potential layers of protection. The core weakness is concentration: the economic value is heavily tied to a limited number of foundational tirzepatide patents. If the principal composition claims fail, secondary formulation and manufacturing patents may not fully preserve market exclusivity.

Strength factors include:

• Core molecule ownership by Lilly.
• Long remaining patent life on important U.S. rights.
• FDA exclusivity through approximately 2027.
• Multiple indications and brands.
• Complex peptide manufacturing and delivery requirements.
• High commercial value that supports extensive litigation.

Risk factors include:

• Paragraph IV invalidity and noninfringement challenges.
• Patent-term uncertainty across jurisdictions.
• Formulation design-around strategies.
• Compounded-product substitution.
• Competing oral and next-generation incretin therapies.
• Reimbursement restrictions that reduce net price before patent expiry.

What is the financial trajectory for Mounjaro?

Mounjaro is moving from launch product to franchise-scale revenue driver. Its 2024 revenue exceeded $11 billion, and combined tirzepatide sales exceeded $16 billion when Zepbound is included. The trajectory depends less on initial demand than on manufacturing capacity, payer access, international approvals, and broader indications.

The main financial sensitivities are:

• Net price after rebates and government discounts.
• U.S. commercial and Medicare coverage.
• Patient persistence and discontinuation.
• Production of pens and injectable fill-finish capacity.
• Competitive efficacy from semaglutide and future incretin therapies.
• Timing of additional indications.
• Patent litigation outcomes.
• Generic or compounded substitution.

Mounjaro and Zepbound have become central to Lilly’s growth profile. The franchise has a longer runway than Mounjaro’s diabetes label alone because the same molecule supports obesity treatment and potential future metabolic indications.

Key Takeaways

• Mounjaro generated $11.54 billion in 2024 revenue.
• Zepbound generated $4.93 billion in 2024, bringing combined tirzepatide revenue to approximately $16.47 billion.
• Tirzepatide accounted for roughly 36.6% of Lilly’s 2024 revenue.
• Mounjaro was FDA-approved in May 2022; Zepbound followed in November 2023.
• NCE exclusivity is expected to run through approximately May 2027.
• Important core tirzepatide patent protection is expected to extend into the mid-2030s.
• The main near-term threats are supply limits, reimbursement pressure, compounded products, and Novo Nordisk’s semaglutide portfolio.
• Mounjaro is a small-molecule peptide drug, so future competition is expected through ANDA or related small-molecule pathways rather than biosimilars.
• The strength of Lilly’s estate depends primarily on the validity and enforceability of its composition-of-matter patents.
• Manufacturing scale is now a major determinant of realized revenue and market share.

FAQs About Mounjaro Market and Patent Outlook

Is Mounjaro more valuable than Trulicity to Eli Lilly?

Yes. Mounjaro’s 2024 revenue of $11.54 billion was several times larger than Trulicity revenue and made tirzepatide one of Lilly’s dominant growth franchises.

Will generic tirzepatide launch before 2036?

An early launch is possible only if a generic applicant succeeds in patent litigation, reaches a settlement with Lilly, or relies on a legally distinct regulatory strategy. If core patents remain valid, broad generic entry is more likely after the mid-2030s.

Are Mounjaro and Zepbound the same drug?

Yes. Both contain tirzepatide. They have different FDA-approved labels, brand names, promotional positioning, and reimbursement treatment.

Can compounded tirzepatide replace Mounjaro commercially?

Compounded tirzepatide can capture some demand, particularly when branded supply is constrained, but its availability depends on federal compounding rules, shortage status, pharmacy practices, quality controls, and litigation.

Does Mounjaro have biosimilar competition?

No. Mounjaro is regulated as a peptide drug rather than a biologic. Its principal future competition would come from generic tirzepatide, 505(b)(2) products, compounded products, and alternative metabolic medicines.

References

1. Eli Lilly and Company. (2025). 2024 annual report.
2. Eli Lilly and Company. (2024). 2023 annual report.
3. Eli Lilly and Company. (2022). Mounjaro prescribing information. U.S. Food and Drug Administration.
4. Eli Lilly and Company. (2025). SURMOUNT-5 topline results: Tirzepatide compared with semaglutide in adults with obesity or overweight.
5. U.S. Food and Drug Administration. (2022, May 13). FDA approves novel, dual-targeted treatment for type 2 diabetes.
6. U.S. Food and Drug Administration. (2023, November 8). FDA approves new medication for chronic weight management, first since 2014.
7. U.S. Patent No. 10,034,938. Peptide compounds. U.S. Patent and Trademark Office.
8. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
9. Eli Lilly and Company. (2024). Lilly announces $5.3 billion investment to expand manufacturing capacity in Indiana.

DrugChatter Q&A for MOUNJARO

Mounjaro slovakia price 2026?
Mounjaro how quickly does it start working?
Mounjaro patent over soon?
Patente mounjaro vencimento?
Quebra de patente mounjaro?